CWC
RXST icon

Carolinas Wealth Consulting’s RxSight RXST Stock Holding History

Carolinas Wealth Consulting’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14
Closed -$548 – 1135
2023
Q4 		$548 Buy
+14
New +$411 ﹤0.01% 905

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Carolinas Wealth Consulting's RXST Position: Q1 2024 in Review

Carolinas Wealth Consulting sold out of RxSight (RXST) in Q1 2024, closing a stake of 14 shares — an estimated $548 sold.

Carolinas Wealth Consulting first reported a position in RXST in Q4 2023 and held it in 1 quarter. The position peaked at $548 in Q4 2023. 197 funds tracked by Wall St. Rank hold RXST as of Q1 2024.

  • Carolinas Wealth Consulting reported no remaining RxSight position as of Q1 2024 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 14 RxSight shares in Q1 2024, an estimated $548.
  • Carolinas Wealth Consulting first reported a position in RxSight in Q4 2023 and held it in 1 quarter.
  • Carolinas Wealth Consulting's RxSight position peaked at $548 in Q4 2023.
  • 197 funds tracked by Wall St. Rank held RxSight as of Q1 2024.

Based on Carolinas Wealth Consulting's 13F filing for Q1 2024, filed 15 May 2024.